What is an active metabolite in simple terms?

It is a chemical product the body makes from a parent compound that still has pharmacological activity. Most metabolites are inert; a small fraction retain activity at one or more receptors and are called active metabolites.

Is 7-OH an active metabolite of mitragynine?

Yes. CYP3A4 in the liver oxidizes a portion of orally consumed mitragynine to 7-hydroxymitragynine, which binds the mu-opioid receptor with substantially higher affinity than mitragynine. 7-OH is the canonical active metabolite of mitragynine in kratom alkaloid pharmacology.

What enzyme converts mitragynine to 7-OH?

The cytochrome P450 enzyme CYP3A4, expressed primarily in the liver and to a lesser extent in the intestinal wall.

Does CYP3A4 inhibition affect 7-OH formation?

In published research models, yes. CYP3A4 inhibitors such as ketoconazole reduce the conversion of mitragynine to 7-OH, while CYP3A4 inducers may increase it. The clinical implications of these findings have not been established.

What is the difference between a prodrug and a parent compound with an active metabolite?

A prodrug is itself pharmacologically inactive and only its metabolite carries activity. A parent compound with an active metabolite is itself active, but its metabolite contributes additional activity. Mitragynine is itself active; 7-OH is a more active metabolite.

Are there other active metabolites of kratom alkaloids?

Yes. Mitragynine pseudoindoxyl, a rearrangement product of 7-OH, is itself a high-affinity MOR partial agonist in published in vitro work.

Alkaloids & Chemistry

Active Metabolite

At-a-glance comparison

Spec	Value
Definition	A metabolic product of a parent compound that retains pharmacological activity
Other names	Pharmacologically active metabolite; bioactive metabolite
Common metabolic pathway	Cytochrome P450 (CYP) oxidation in the liver
Kratom example	7-Hydroxymitragynine, the CYP3A4-mediated active metabolite of mitragynine
Other notable examples	Morphine from codeine (CYP2D6); desipramine from imipramine; norfluoxetine from fluoxetine
Why it matters	Many compounds derive most of their in vivo activity from active metabolites; understanding the metabolite is essential to interpreting pharmacology

What is an active metabolite?

When a compound is consumed orally and reaches the bloodstream, the body chemically modifies it through a series of metabolic reactions - most commonly oxidation, reduction, hydrolysis, and conjugation - collectively called metabolism. The products of these reactions are called metabolites. Most metabolites are pharmacologically inert end products destined for elimination. A subset, however, retains pharmacological activity at one or more receptors. Those are active metabolites.

Active metabolites are clinically and scientifically important because the apparent activity of an orally consumed compound is often a composite of the parent compound and its active metabolites. In some cases the active metabolite produces the majority of the in vivo effect; in others it contributes alongside the parent compound; in still others the parent is itself inactive and only the metabolite carries activity (in which case the parent is called a prodrug).

7-Hydroxymitragynine as the active metabolite of mitragynine

In kratom alkaloid pharmacology, 7-hydroxymitragynine is the canonical active metabolite. When mitragynine - the dominant alkaloid of Mitragyna speciosa - is consumed orally, the cytochrome P450 enzyme CYP3A4 in the liver oxidizes a portion of the dose at the 7-position of the indole ring system to produce 7-OH. Although 7-OH is present at only trace concentrations in fresh kratom leaf, this hepatic conversion generates a meaningful exposure to 7-OH following oral mitragynine consumption.

What makes 7-OH a clinically important metabolite rather than a pharmacologically incidental one is its receptor-pharmacology profile. In published in vitro work, 7-OH binds the mu-opioid receptor with affinity reported as five to twenty-two times greater than mitragynine across published assay systems, and it is also a G-protein-biased partial agonist at the receptor. Even a small fraction of mitragynine converted to 7-OH therefore contributes substantially to the in vivo pharmacological profile of orally consumed kratom material.

Other examples of active metabolites in pharmacology

The active-metabolite paradigm is widespread in pharmacology. Codeine is a classical example: the parent compound has weak activity, but CYP2D6 in the liver demethylates a portion of the dose to morphine, which carries the bulk of the parent compound's effect. The antidepressant fluoxetine is metabolized to norfluoxetine, which is itself an active inhibitor of serotonin reuptake. Many compounds across pharmacology derive a meaningful fraction of their activity from active metabolites.

Understanding which metabolites are active and which CYP enzymes generate them is central to interpreting pharmacology and to anticipating drug-drug interactions. CYP3A4 is involved in the metabolism of many compounds; co-administration of a CYP3A4 inhibitor or inducer can therefore meaningfully alter the exposure to the active metabolite of any compound that depends on CYP3A4 for that metabolite generation.

Common questions about active metabolite

What is an active metabolite in simple terms?: It is a chemical product the body makes from a parent compound that still has pharmacological activity. Most metabolites are inert; a small fraction retain activity at one or more receptors and are called active metabolites.
Is 7-OH an active metabolite of mitragynine?: Yes. CYP3A4 in the liver oxidizes a portion of orally consumed mitragynine to 7-hydroxymitragynine, which binds the mu-opioid receptor with substantially higher affinity than mitragynine. 7-OH is the canonical active metabolite of mitragynine in kratom alkaloid pharmacology.
What enzyme converts mitragynine to 7-OH?: The cytochrome P450 enzyme CYP3A4, expressed primarily in the liver and to a lesser extent in the intestinal wall.
Does CYP3A4 inhibition affect 7-OH formation?: In published research models, yes. CYP3A4 inhibitors such as ketoconazole reduce the conversion of mitragynine to 7-OH, while CYP3A4 inducers may increase it. The clinical implications of these findings have not been established.
What is the difference between a prodrug and a parent compound with an active metabolite?: A prodrug is itself pharmacologically inactive and only its metabolite carries activity. A parent compound with an active metabolite is itself active, but its metabolite contributes additional activity. Mitragynine is itself active; 7-OH is a more active metabolite.
Are there other active metabolites of kratom alkaloids?: Yes. Mitragynine pseudoindoxyl, a rearrangement product of 7-OH, is itself a high-affinity MOR partial agonist in published in vitro work.

References

Kamble SH, Sharma A, King TI, et al. (2020). Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicology Letters.
Kruegel AC, Gassaway MM, Kapoor A, et al. (2016). Synthetic and receptor signaling explorations of the Mitragyna alkaloids. JACS.
Wilson LL, Harris HM, Eans SO, et al. (2020). Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug and Alcohol Dependence.
U.S. Food and Drug Administration. (2020). Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry.

Important safety information:

Products containing 7-hydroxymitragynine (7-OH) are sold for adult use only (21+). These statements have not been evaluated by the U.S. Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease. The FDA has raised safety concerns regarding concentrated 7-OH products; consult a qualified healthcare professional before use. Do not operate vehicles or machinery after use. Keep out of reach of children and pets. Laws vary by state, buyers are responsible for knowing applicable law.